Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

A new drug class that is currently being investigated is the OX40 inhibitor, which targets OX40 receptors and ligands. OX40 inhibitors may be promising as AD treatments, as key opinion leaders ...

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

KY1005 – now renamed amlitelimab – is one of a handful of new drugs targeting OX40 ligand, an immune system regulator delivered by intravenous infusion once every 28 days. It is also being ...

ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary ...

For these reasons, molecules targeting direct activation of immune cells, including antibodies to receptors such as OX40, CD40 and others on immune cells with a stimulatory mechanism of action ...

The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, ...